How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?

Atherosclerosis. 2024 Jun:393:117551. doi: 10.1016/j.atherosclerosis.2024.117551. Epub 2024 Apr 16.
No abstract available

Keywords: Evinacumab; Homozygous familial hypercholesterolemia; Lipoprotein apheresis; Lomitapide; PCSK9 inhibitor; Statin.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Biomarkers / blood
  • Cholesterol, LDL / blood
  • Genetic Predisposition to Disease
  • Homozygote*
  • Humans
  • Hyperlipoproteinemia Type II* / blood
  • Hyperlipoproteinemia Type II* / diagnosis
  • Hyperlipoproteinemia Type II* / genetics
  • Hyperlipoproteinemia Type II* / therapy
  • Mutation
  • Phenotype
  • Prognosis
  • Receptors, LDL / genetics
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Receptors, LDL
  • Anticholesteremic Agents
  • Biomarkers